TY - JOUR
T1 - Role of pitrm1 in mitochondrial dysfunction and neurodegeneration
AU - Brunetti, Dario
AU - Catania, Alessia
AU - Viscomi, Carlo
AU - Deleidi, Michela
AU - Bindoff, Laurence A.
AU - Ghezzi, Daniele
AU - Zeviani, Massimo
N1 - Funding Information:
Funding: This research was funded by the University of Milan, grant SoE-SEED2020_MI.to.AD (to D.G. and D.B.), by the Foundation Telethon-Italy, grant GSP20003_PAsAtaxia002 (to D.B.), GGP19007 (to M.Z.) and GGP20013 (to C.V.) by the Telethon Foundation, Helmholtz Association Young Investigator Award (VH-NG-1123, to M.D.).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/7
Y1 - 2021/7
N2 - Mounting evidence shows a link between mitochondrial dysfunction and neurodegenerative disorders, including Alzheimer Disease. Increased oxidative stress, defective mitodynamics, and impaired oxidative phosphorylation leading to decreased ATP production, can determine synaptic dysfunction, apoptosis, and neurodegeneration. Furthermore, mitochondrial proteostasis and the protease-mediated quality control system, carrying out degradation of potentially toxic peptides and misfolded or damaged proteins inside mitochondria, are emerging as potential pathogenetic mechanisms. The enzyme pitrilysin metallopeptidase 1 (PITRM1) is a key player in these processes; it is responsible for degrading mitochondrial targeting sequences that are cleaved off from the imported precursor proteins and for digesting a mitochondrial fraction of amyloid beta (Aβ). In this review, we present current evidence obtained from patients with PITRM1 mutations, as well as the different cellular and animal models of PITRM1 deficiency, which points toward PITRM1 as a possible driving factor of several neurodegenerative conditions. Finally, we point out the prospect of new diagnostic and therapeutic approaches.
AB - Mounting evidence shows a link between mitochondrial dysfunction and neurodegenerative disorders, including Alzheimer Disease. Increased oxidative stress, defective mitodynamics, and impaired oxidative phosphorylation leading to decreased ATP production, can determine synaptic dysfunction, apoptosis, and neurodegeneration. Furthermore, mitochondrial proteostasis and the protease-mediated quality control system, carrying out degradation of potentially toxic peptides and misfolded or damaged proteins inside mitochondria, are emerging as potential pathogenetic mechanisms. The enzyme pitrilysin metallopeptidase 1 (PITRM1) is a key player in these processes; it is responsible for degrading mitochondrial targeting sequences that are cleaved off from the imported precursor proteins and for digesting a mitochondrial fraction of amyloid beta (Aβ). In this review, we present current evidence obtained from patients with PITRM1 mutations, as well as the different cellular and animal models of PITRM1 deficiency, which points toward PITRM1 as a possible driving factor of several neurodegenerative conditions. Finally, we point out the prospect of new diagnostic and therapeutic approaches.
KW - Alzheimer Disease
KW - Mitochondrial dysfunction
KW - Mitochondrial protein quality control
KW - Mitochondrial proteostasis
KW - Neurodegeneration
KW - Neurodegenerative dementia
KW - Neurodegenerative diseases
KW - Pitrilysin metallopeptidase 1
KW - PITRM1
KW - Protein aggregation
KW - Spinocerebellar ataxia
UR - http://www.scopus.com/inward/record.url?scp=85111395018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111395018&partnerID=8YFLogxK
U2 - 10.3390/biomedicines9070833
DO - 10.3390/biomedicines9070833
M3 - Review article
AN - SCOPUS:85111395018
SN - 2227-9059
VL - 9
JO - Biomedicines
JF - Biomedicines
IS - 7
M1 - 833
ER -